PT-141
Melanocortin Receptor Agonist — Sexual Function Research
PT-141 (bremelanotide) is a melanocortin receptor agonist that acts centrally on MC3R and MC4R receptors in the brain to enhance sexual motivation and arousal — a fundamentally different mechanism from vasodilatory drugs like sildenafil, which act peripherally on blood flow.
At a Glance
The melanocortin system governs multiple physiological functions including energy balance, pigmentation, and sexual function. PT-141 was originally developed from Melanotan II but re-engineered to remove the UV-tanning effects while retaining and amplifying the central sexual arousal mechanism.
Its CNS mechanism means it can address desire and motivation deficits — not just physical arousal — making it relevant for hypoactive sexual desire disorder (HSDD) research in both men and women.
FDA approval for HSDD in premenopausal women (as Vyleesi) validates the melanocortin mechanism for sexual function — and Phase 2 data in men with erectile dysfunction unresponsive to PDE5 inhibitors has also been generated.
This compound operates through several converging biological pathways, which helps explain the breadth of effects observed across different tissue and metabolic models.
MC3R/MC4R Agonism in CNS
Activates melanocortin 3 and 4 receptors in hypothalamic and limbic regions governing sexual motivation, desire, and arousal initiation.
Central vs Peripheral Mechanism
Acts on brain-level desire circuits rather than peripheral vasculature — addressing sexual motivation rather than just blood flow mechanics.
Hypothalamic Arousal Pathways
Engages melanocortin neurons in the medial preoptic area and paraventricular nucleus — key hypothalamic centers in sexual behavior regulation.
Rapid Onset
SC administration produces onset within 45 minutes — practical for demand-driven dosing in research protocols.
Preclinical and clinical models have investigated this compound across a wide range of physiological contexts and tissue types.
- Hypoactive sexual desire disorder (HSDD) — FDA-approved indication in premenopausal women
- Male erectile dysfunction — particularly PDE5-inhibitor non-responders
- Central vs peripheral sexual function mechanisms — comparative research
- Melanocortin system in sexual behavior — MC3R/MC4R pathway characterization
- Female sexual dysfunction — desire vs arousal distinction research
- Combination with PDE5 inhibitors — central + peripheral dual mechanism studies
- Sexual function in hormonal conditions — hypogonadism, menopause research
PT-141's central mechanism fills a gap that peripheral vasodilators cannot — addressing desire and motivation deficits that originate in the brain rather than the vasculature.
PT-141, sildenafil, and flibanserin represent three mechanistically distinct approaches to sexual function research — central desire, peripheral mechanics, and serotonergic mood.
| Aspect | PT-141 | Sildenafil (reference) | Flibanserin (reference) |
|---|---|---|---|
| Mechanism | Melanocortin agonist (CNS) | PDE5 inhibitor (peripheral) | 5-HT1A agonist / 5-HT2A antagonist |
| Target | Sexual desire/motivation | Vascular erectile mechanics | Desire / mood |
| FDA Approved | Yes — Vyleesi (HSDD women) | Yes — ED | Yes — Addyi (HSDD women) |
| CNS or Peripheral | Central (CNS) | Peripheral | Central (CNS) |
| Onset | ~45 minutes | ~30–60 minutes | Chronic (daily dosing) |
The following reflects findings from published preclinical and clinical safety assessments where available.
FDA approved for HSDD — Phase 3 data available with validated mechanism
CNS mechanism — addresses desire deficit that peripheral drugs cannot
Works in PDE5 non-responders — clinically validated for men who don't respond to sildenafil
Nausea and blood pressure — common adverse effects; transient flushing, nausea, and mild BP elevation in Phase 3
This overview is strictly educational and based on publicly available scientific literature as of 2026. It does not constitute medical advice. All Helixera Labs products are for laboratory research use only. Not for human or veterinary use. · Helixera Labs LLC © 2026